Cancer Research and Treatment

Original Article

General

Low-Dose Cyclophosphamide Enhances the Tumoricidal Effects of 5-Day Spacing Stereotactic Ablative Radiotherapy by Boosting Antitumor Immunity: Hyunkyung Kim, Seok-Joo Chun, Sojung Sun, Haeun Cho, Tae-Jin Kim, Yoon-Jin Lee, Eui Kyu Chie, Kwangmo Yang, Mi-Sook Kim; Cancer Res Treat. 2025;57(3):678-692. Published online November 8, 2024; DOI: https://doi.org/10.4143/crt.2024.807

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the potential role of low-dose cyclophosphamide (Cy) as a radiosensitizer by evaluating its impact on the immune response and the abscopal effect of stereotactic ablative radiotherapy through preclinical models.
Materials and Methods
CT26 tumors (immunologically hot) and 4T1 tumors (immunologically cold), grown in immunocompetent BALB/c and immunodeficient BALB/c–nude mice, were irradiated with 20 Gy in two fractions with 5-day spacing followed by intraperitoneal injections of 9 mg/kg Cy every 3 days. Immunological changes in CT26 tumors caused by the treatments were assessed using flow cytometry. Changes in the expression of hypoxia-inducible factor-1α (HIF-1α) in tumors were also assessed. Splenocytes and bone marrow–derived dendritic cells (DCs) were exposed to various concentrations of Cy to assess T cell proliferation and DC differentiation.
Results
The combination of Cy with radiotherapy (RT+Cy) significantly suppressed tumor growth compared to RT alone in immunocompetent mice, while that effect was not observed in immunodeficient mice. Additionally, RT+Cy effectively induced abscopal effects in hot and cold tumors, with increased CD8+ T cells in blood and tumors. Significantly higher expression levels of granzyme B, interferon γ, and tumor necrosis factor α were observed in RT+Cy group compared to the RT alone group. In vitro data indicated that low-dose Cy promotes DC differentiation. Low-dose Cy suppressed the radiation-induced upregulation of HIF-1α in the tumors.
Conclusion
Low-dose Cy enhances tumoricidal effects of 5-day spacing high-dose RT by increasing antitumor immune responses.

Citations

Citations to this article as recorded by

Regulatory T cells in cancer: from immunosuppression to therapeutic targeting
Paola Basurto-Olvera, Hector Serrano, Carmen Maldonado-Bernal
Frontiers in Immunology.2025;[Epub] CrossRef
Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients
Jessica Oliver, Hannah Reed, Lorenzo Capitani, Ashley Poon-King, Ashleigh Young, Stefan Milutinovic, Mateusz Kuczynski, Owen Nicholas, Thomas Rackley, Catherine Pembroke, Andrew Godkin, Awen M. Gallimore
Cancer Immunology, Immunotherapy.2025;[Epub] CrossRef

3,770 View
134 Download
2 Web of Science
2 Crossref

Review Article

Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy: Chang W Song, Hyunkyung Kim, Mi-Sook Kim, Heon J Park, Sun-Ha Paek, Stephanie Terezakis, L Chinsoo Cho; Cancer Res Treat. 2025;57(1):1-10. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.255

Abstract PDF PubReader ePub

Tumor microenvironment is intrinsically hypoxic with abundant hypoxia-inducible factors-1α (HIF-1α), a primary regulator of the cellular response to hypoxia and various stresses imposed on the tumor cells. HIF-1α increases radioresistance and chemoresistance by reducing DNA damage, increasing repair of DNA damage, enhancing glycolysis that increases antioxidant capacity of tumors cells, and promoting angiogenesis. In addition, HIF-1α markedly enhances drug efflux, leading to multidrug resistance. Radiotherapy and certain chemotherapy drugs evoke profound anti-tumor immunity by inducing immunologic cell death that release tumor-associated antigens together with numerous pro-immunological factors, leading to priming of cytotoxic CD8+ T cells and enhancing the cytotoxicity of macrophages and natural killer cells. Radiotherapy and chemotherapy of tumors significantly increase HIF-1α activity in tumor cells. Unfortunately, HIF-1α effectively promotes various immune suppressive pathways including secretion of immune suppressive cytokines, activation of myeloid-derived suppressor cells, activation of regulatory T cells, inhibition of T cells priming and activity, and upregulation of immune checkpoints. Consequently, the anti-tumor immunity elevated by radiotherapy and chemotherapy is counterbalanced or masked by the potent immune suppression promoted by HIF-1α. Effective inhibition of HIF-1α may significantly increase the efficacy of radiotherapy and chemotherapy by increasing radiosensitivity and chemosensitivity of tumor cells and also by upregulating anti-tumor immunity.

Citations

Citations to this article as recorded by

Enhancing the sensitivity of radiotherapy in non-small cell lung cancer through nanotechnology-mediated reactive oxygen species generation
Xueying Bao, Zhuangzhuang Zheng, Man Li, Xuanzhong Wang, Qin Zhao, Huanhuan Wang, Ying Xin, Xin Jiang
Coordination Chemistry Reviews.2026; 549: 217234. CrossRef
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma
Yudi Liu, Ling Xiao, Xinyu Nie, Jiahua Lyu, Chengxi Tang, Linjie Li, Xue Zhang, Tao Li, Jianming Huang, Shichuan Zhang
Cancer Biology & Therapy.2026;[Epub] CrossRef
Innovative applications and future prospects of Raman spectroscopy in precision management of cancer radiotherapy and chemotherapy
Mingyu Zhang, Linlin Shao, Mingyue Ma, Ying Liu, Xin Wang, Bing Han
Applied Spectroscopy Reviews.2026; : 1. CrossRef
Historical Review of the Role of Indirect Cell Death in High-Dose Per Fraction Radiation Therapy
Chang W. Song, Lindsey Sloan, Stephanie Terezakis, Kyungmi Yang, Robert J. Griffin
Advances in Radiation Oncology.2026; 11(3): 101971. CrossRef
Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma
Emirhan Harbi, Yasemin Yozgat Byrne, Hamza Ugur Bozbey, Didem Tastekin, Oral Oncul, Soha Hosseiny, Duha Yahya, Ozcan Yildiz, Murat Erdogan, Abdul Kadir Slocum, Christopher E. Mason, Michael Aschner
Apoptosis.2026;[Epub] CrossRef
Paeoniflorigenone inhibits the progression of cholangiocarcinoma via HIF1A and enhances the chemotherapy sensitivity of cisplatin
Qing Hu, Mengqin Xiang, Feicheng Yang, Wei Guo, Mengjun Mo, Zhou Yang, Yanchun Li
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Down-regulation of PCK2 enhanced the radioresistance phenotype of nasopharyngeal carcinoma
Yijun He, Li Yan, Ruiqi Zhang, Rui Yang, Zhaolu Kong, Xiaosheng Wang
International Journal of Radiation Biology.2025; 101(5): 499. CrossRef
Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer
Lingyan Weng, Min Zhao, Zhongping Chen, Li Zhu
Molecular Pharmaceutics.2025; 22(4): 2142. CrossRef
Rhaponitin Reverses Cisplatin Resistance and Impairs Cancer Stemness Through HIF‐1α/MCT4/Wnt Pathway in Tongue Squamous Cell Carcinoma
Yuan Wu, Xiao‐Wen Wan, Lin Jiang, Wei Wang, Jia‐Jun Zhu, Yi‐Sen Shao
The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Stereotactic Ablative Radiotherapy for Delayed Retrobulbar Metastasis of Renal Cell Carcinoma: Therapeutic Outcomes and Practical Insights
Sang Jun Byun, Byung Hoon Kim, Seung Gyu Park, Euncheol Choi
Life.2025; 15(8): 1176. CrossRef
Low-Dose Cyclophosphamide Enhances the Tumoricidal Effects of 5-Day Spacing Stereotactic Ablative Radiotherapy by Boosting Antitumor Immunity
Hyunkyung Kim, Seok-Joo Chun, Sojung Sun, Haeun Cho, Tae-Jin Kim, Yoon-Jin Lee, Eui Kyu Chie, Kwangmo Yang, Mi-Sook Kim
Cancer Research and Treatment.2025; 57(3): 678. CrossRef
Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy
Gregg L. Semenza
Pharmacological Reviews.2025; 77(5): 100075. CrossRef
Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting
Mahdieh Ameri Shah Reza, Saina Najafi, Masoumeh Kahfi, Mustafa Safari, Mohamad Mahjoor
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance
Xiaoliang Cheng, Peixing Wang, Hongqiang Lyu, Yonghyun Lee, Juyoung Yoon, Haiyan Dong
Cancer Drug Resistance.2025;[Epub] CrossRef
FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation
Valérie Gouazé-Andersson, Caroline Delmas, Yvan Nicaise, Julien Nicolau, Juan Pablo Cerapio, Elizabeth Cohen-Jonathan Moyal
Cells.2025; 14(18): 1427. CrossRef
Glycolysis-related radiosensitivity signature for predicting radiotherapy response in breast cancer
Xuan Lin, Shiyin Hu, Linyan Huang, Tianwen Xu, Jinzhi Lai
Frontiers in Immunology.2025;[Epub] CrossRef
Interrogating ABCC1 and CASP1 as key players in epigallocatechin gallate’s action against radiotherapy-resistant nasopharyngeal carcinoma
Zhang Feng, Yuhang Yang, Zhenlian Xie, Long Zuo, Zhenya Li, Congbao Wei, Jinqing Li, Yanyong Gao, Zifang Li, Dongzhi Zuo, Qianghe Liu, Guangxu Xuan, Wenqi Luo, Xuejing Tang, Shijiang Yi, Fangxian Liu, Ning Ma, Mariko Murata, Feng He
Scientific Reports.2025;[Epub] CrossRef
Concerns from bench and insights from bedside: the puzzle of Roxadustat in cancer patients with chemotherapy-induced anemia
Lin Chen, Shigen Liao, Dan Jing, Linxiu Mao, Jing Tan
Frontiers in Pharmacology.2025;[Epub] CrossRef
Role of hypoxia factors in the transcriptional mechanisms of clonal hematopoiesis in myelodysplastic syndrome
V. A. Nevzorova, A. S. Volosatov, A. V. Talko, N. S. Muzychenko, V. S. Dubov, V. M. Chertok
Pacific Medical Journal.2025; (3): 11. CrossRef

8,009 View
302 Download
19 Web of Science
19 Crossref

First
Prev
Page of 1
Next
Last

Search